---
title: "I-Mab Rebrands to NovaBridge Biosciences Following Shareholder Approval"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/262687259.md"
description: "I-Mab has rebranded to NovaBridge Biosciences following shareholder approval on October 24, 2025. The name change aims to enhance brand identity and align with strategic goals. Analysts rate IMAB stock as a Buy with a $9.00 price target, but Spark's AI Analyst gives it a Neutral rating due to financial challenges and ongoing losses. I-Mab focuses on developing therapies for immuno-oncology and autoimmune diseases, with a current market cap of $381.7M."
datetime: "2025-10-24T20:50:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/262687259.md)
  - [en](https://longbridge.com/en/news/262687259.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/262687259.md)
---

# I-Mab Rebrands to NovaBridge Biosciences Following Shareholder Approval

An update from I-MAB ( (IMAB) ) is now available.

On October 24, 2025, I-Mab held an extraordinary general meeting where shareholders approved changing the company’s name to NovaBridge Biosciences. Additionally, the shareholders agreed to amend and restate the company’s memorandum and articles of association, reflecting the new name and updated governance structure. These changes are expected to enhance the company’s brand identity and align its corporate structure with strategic goals.

The most recent analyst rating on (IMAB) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on I-MAB stock, see the IMAB Stock Forecast page.

**Spark’s Take on IMAB Stock**

According to Spark, TipRanks’ AI Analyst, IMAB is a Neutral.

The overall stock score of 45 reflects I-MAB’s substantial financial challenges, particularly in terms of profitability and cash flow generation, which heavily impact its financial performance. Despite a modest technical uptrend, valuation metrics point to significant risks, with ongoing losses and a negative P/E ratio limiting its appeal. The absence of recent earnings call data or notable corporate events further solidifies the overall cautious outlook.

To see Spark’s full report on IMAB stock, click here.

**More about I-MAB**

I-Mab is a company in the biotechnology industry, focusing on developing innovative therapies. Its market focus includes the development and commercialization of biologics for immuno-oncology and autoimmune diseases.

**Average Trading Volume:** 2,680,252

**Technical Sentiment Signal:** Buy

**Current Market Cap:** $381.7M

For a thorough assessment of IMAB stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [IMAB.US](https://longbridge.com/en/quote/IMAB.US.md)
- [NBP.US](https://longbridge.com/en/quote/NBP.US.md)

## Related News & Research

- [Harmony Biosciences (HRMY) Stock Looks Below Fair Value On Earnings](https://longbridge.com/en/news/294590505.md)
- [Prediction: Eli Lilly Will Be Worth $2 Trillion by 2031](https://longbridge.com/en/news/294589601.md)
- [Dyne Therapeutics (DYN) Could Be 38% Undervalued As FDA Milestones Lift Pipeline Hopes](https://longbridge.com/en/news/294589043.md)
- [Bristol Myers Squibb Isn't Nearly as Cheap as It Looks -- Here's the 1 Thing That Could Change That](https://longbridge.com/en/news/294582182.md)
- [Why Replimune (REPL) Is Up 15.5% After Supportive FDA Panel Vote On IGNYTE Melanoma Data](https://longbridge.com/en/news/294586250.md)